Lundbeck Q3 2019 Financial Results
Three new projects enter first-in-humans testing
Lu AF884341)
Lu AF88434 is a potent and
selective phosphodiesterase
PDE 1b inhibitor (PDE1b-i)
Lu AF879082)
*
Lu AF87908 is a humanized
大
IgG1 Tau mAb
*
SAD study in healthy
SAD study investigating the
safety, tolerability, PK/PD
properties of Lu AF88434
*
N = ~100 participants
大
N = ~66 participants
PDE1 is highly expressed in
brain regions involved in
cognitive processing
Potential cognitive enhancer
- e.g. in schizophrenia and
Alzheimer's (AD)
*
subjects and AD patients
Delay disease progression in
AD or other tauopathies
**
1) Clinicaltrials.gov ID: NCT04082325
37
2) NCT04149860
Immunoglobulin G1 (Ig) is types of antibodies (Ab)
Lu AG09222
Lu AG09222 mAb inhibits
pituitary adenylate cyclase-
activating polypeptide
(PACAP)
N = ~100 participants
PACAP is an important
signalling molecule in the
pathophysiology of
migraine
Landbec⭑View entire presentation